2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153535
    THRβ receptor agonist-1 2403721-00-4 98%
    THRβ receptor agonist-1 is a THRβ receptor agonist.
    THRβ receptor agonist-1
  • HY-153538
    AP-C2 682793-07-3 98%
    AP-C2 is a potent guanosine 3',5'-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) inhibitor with a pIC50 of 5.2.
    AP-C2
  • HY-153667
    MK-2305 2101206-49-7 98%
    MK-2305 is an orally active GPR40 partial agonist with an EC50 of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes.
    MK-2305
  • HY-153706
    URAT1 inhibitor 5 2102670-94-8 98%
    URAT1 inhibitor 5 (compound 16) is a potent URAT1 inhibitor. URAT1 inhibitor 5 can be used in research of hyperuricemia.
    URAT1 inhibitor 5
  • HY-153759
    CRX000227 686769-92-6
    CRX000227 is a PPAR modulator. CRX000227 can be used for research of metabolic or cell proliferative disorders.
    CRX000227
  • HY-153760
    GSK-3β inhibitor 14 863004-48-2 99.92%
    GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC50 >100 μM).
    GSK-3β inhibitor 14
  • HY-153875
    Saccharolactone 389-36-6 98%
    Saccharolactone is a potent orally active β-glucuronidase inhibitor. Saccharolactone markedly lowers biliary endogenous β-glucuronidase activity in the rat bile. Saccharolactone can stabilize glucuronide metabolites in vitro. Saccharolactone is also a strong inhibitor of CYP1A2, 2D6, 3A4 and 2C8 isoforms (IC50 < 4 mM).
    Saccharolactone
  • HY-153938
    PROTAC PTPN2 degrader-2 2912307-38-9 98%
    PROTAC PTPN2 degrader-2 is a potent PTPN2 PROTAC degrader with a DC50 of <50 nM. PROTAC PTPN2 degrader-2 is potential for studying cancer or metabolic diseases, such as colon cancer.
    PROTAC PTPN2 degrader-2
  • HY-153982
    PPARγ agonist 8 1049800-41-0 98%
    PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC50 of 0.2 μM.
    PPARγ agonist 8
  • HY-15408S
    Trelagliptin-13C,d3 2707203-34-5 98%
    Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin. Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC50 of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM).
    Trelagliptin-13C,d3
  • HY-154972
    α-Amylase/α-Glucosidase-IN-3 98%
    α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus.
    α-Amylase/α-Glucosidase-IN-3
  • HY-154973
    AMPK activator 11 2948304-00-3 98%
    AMPK activator 11 is an AMP-activated protein kinase (AMPK) activator with nanomolelevel antiproliferation activities against several CRCs. AMPK activator 11 selectively inhibits the RKO xenograft growth along by activating AMPK and upregulating oxidative phosphorylation (OXPHOS) ( mitochondrial metabolism ) and can be used for anti-tumor and metabolic disease research.
    AMPK activator 11
  • HY-154985
    DSO-5a 2195411-63-1 98%
    DSO-5a is a potent, selective, orally active BB3 agonist. DSO-5a is a representative DMAKO-00 derivative compound. DSO-5a upregulates ppar-γ activity through BB3 and activates ERK1/2 phosphorylation. DSO-5a can be used in diabetes-related research.
    DSO-5a
  • HY-154998
    α-Glucosidase-IN-27 98%
    α-Glucosidase-IN-27 (compound 8l) is an α-glucosidase inhibitor (IC50=25.78 μM). α-Glucosidase-IN-27 has the potential to study type 2 diabetes (D2M).
    α-Glucosidase-IN-27
  • HY-155006
    PCSK9-IN-19 98%
    PCSK9-IN-19 (Compound 1) is a PCSK9 inhibitor. PCSK9-IN-19 can be used for research of high LDL-cholesterol levels and prevention of coronary artery disease.
    PCSK9-IN-19
  • HY-155010
    Steroid sulfatase/17β-HSD1-IN-5 3033655-07-8 98%
    Steroid sulfatase/17β-HSD1-IN-5 is a irreversible inhibitor of steroid sulfatase (STS) .Steroid sulfatase/17β-HSD1-IN-5 is a reversible and selective inhibitor of 7β-hydroxysteroid dehydrogenase type1 (17β-HSD1), with IC50s of 43 nM and 6.2μM for 17β-HSD1 and 17β-HSD2, respectively. Steroid sulfatase/17β-HSD1-IN-5 can be used for metabolic disease (especially for endometriosis) research.
    Steroid sulfatase/17β-HSD1-IN-5
  • HY-155030
    α-Glucosidase-IN-25 2941473-92-1 98%
    α-Glucosidase-IN-25 (Compound (R)-8k) is a competitive inhibitor of α-glucosidase, with an IC50 of 1.19μM and can be used for anti-diabetic research.
    α-Glucosidase-IN-25
  • HY-155064
    TRAP1-IN-2 3031102-92-5 98%
    TRAP1-IN-2 (compound 36) is a selective degrader of TRAP1 downstream proteins without affecting Hsp90's cytoplasmic downstream proteins. TRAP1-IN-2 also inhibits OXPHOS and alters cellular glycolysis metabolism. TRAP1-IN-2 destabilizes TRAP1 tetramers and disrupts mitochondrial membrane potential.
    TRAP1-IN-2
  • HY-155088
    MK-8768 1432729-22-0 98%
    MK-8768 is a highly potent, orally bioavailable and selective class of mGluR2 negative allosteric modulator (IC50 of 9 .6nM) with excellent brain permeability.
    MK-8768
  • HY-155105
    α-Glucosidase-IN-30 2966859-35-6 98%
    α-Glucosidase-IN-30 (compound 8c) is a potent, orally active, competitive inhibitor against α-glucosidase, with Ki  of 40.0 µM and IC50 value of 49.0 µM. α-Glucosidase-IN-30 is non-cytotoxic against the cancer and normal cell lines MCF-7 and HDF, and can be used for Type 2 diabetes study.
    α-Glucosidase-IN-30
Cat. No. Product Name / Synonyms Application Reactivity